Peroxisome Proliferator-activated Receptorα/γ Agonist Pioglitazone for Rescuing Relapsed or Refractory Neoplasias by Unlocking Phenotypic Plasticity

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jan 26

PMID 38273846

Authors

Dennis Christoph Harrer

Florian Luke

Tobias Pukrop

Lina Ghibelli

Christopher Gerner

Albrecht Reichle

Daniel Heudobler

Affiliations

Soon will be listed here.

Abstract

A series of seven clinical trials on relapsed or refractory (r/r) metastatic neoplasias followed the question: Are networks of ligand-receptor cross-talks that support tumor-specific cancer hallmarks, druggable with tumor tissue editing approaches therapeutically exploiting tumor plasticity? Differential recombinations of pioglitazone, a dual peroxisome-proliferator activated receptor (PPARα/γ) agonist, with transcriptional modulators, i.e., all-trans retinoic acid, interferon-α, or dexamethasone plus metronomic low-dose chemotherapy (MCT) or epigenetic modeling with azacitidine plus/minus cyclooxygenase-2 inhibition initiated tumor-specific reprogramming of cancer hallmarks, as exemplified by inflammation control in r/r melanoma, renal clear cell carcinoma (RCCC), Hodgkin's lymphoma (HL) and multisystem Langerhans cell histiocytosis (mLCH) or differentiation induction in non-promyelocytic acute myeloid leukemia (non-PML AML). Pioglitazone, integrated in differentially designed editing schedules, facilitated induction of tumor cell death as indicated by complete remission (CR) in r/r non-PML AML, continuous CR in r/r RCCC, mLCH, and in HL by addition of everolimus, or long-term disease control in melanoma by efficaciously controlling metastasis, post-therapy cancer repopulation and acquired cell-resistance and genetic/molecular-genetic tumor cell heterogeneity (M-CRAC). PPARα/γ agonists provided tumor-type agnostic biomodulatory efficacy across different histologic neoplasias. Tissue editing techniques disclose that wide-ranging functions of PPARα/γ agonists may be on-topic focused for differentially unlocking tumor phenotypes. Low-dose MCT facilitates targeted reprogramming of cancer hallmarks with transcriptional modulators, induction of tumor cell death, M-CRAC control and editing of non-oncogene addiction. Thus, pioglitazone, integrated in tumor tissue editing protocols, is an important biomodulatory drug for addressing urgent therapeutic problems, such as M-CRAC in relapsed or refractory tumor disease.

References

Biziota E, Mavroeidis L, Hatzimichael E, Pappas P . Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2016; 400:243-251. DOI: 10.1016/j.canlet.2016.12.018. View

Corsi F, Capradossi F, Pelliccia A, Briganti S, Bruni E, Traversa E . Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer. Int J Mol Sci. 2022; 23(3). PMC: 8834753. DOI: 10.3390/ijms23031152. View

Wang M, Li G, Yang Z, Wang L, Zhang L, Wang T . Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer. Oncotarget. 2017; 8(5):8083-8094. PMC: 5352384. DOI: 10.18632/oncotarget.14097. View

Grunwald B, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey C . Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021; 184(22):5577-5592.e18. DOI: 10.1016/j.cell.2021.09.022. View

Petroni G, Buque A, Coussens L, Galluzzi L . Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov. 2022; 21(6):440-462. DOI: 10.1038/s41573-022-00415-5. View

Canil C, Hotte S, Mayhew L, Waldron T, Winquist E . Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Can Urol Assoc J. 2010; 4(3):201-8. PMC: 2874597. DOI: 10.5489/cuaj.853. View

Tao Z, Wu X . Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable". Methods Mol Biol. 2022; 2594:107-131. PMC: 9724592. DOI: 10.1007/978-1-0716-2815-7_9. View

Takano S, Kubota T, Nishibori H, Hasegawa H, Ishii Y, Nitori N . Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res. 2009; 28(6A):3593-9. View

Kitamura S, Miyazaki Y, Hiraoka S, Nagasawa Y, Toyota M, Takakura R . PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int J Cancer. 2001; 94(3):335-42. DOI: 10.1002/ijc.1470. View

10.

Kumar V, Nambiar R, De Souza C, Nguyen A, Chien J, Lam K . Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior. Cells. 2022; 11(9). PMC: 9102449. DOI: 10.3390/cells11091403. View

11.

Schmitt M, Ceteci F, Gupta J, Pesic M, Bottger T, Nicolas A . Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation. Nature. 2022; 612(7939):347-353. PMC: 7613947. DOI: 10.1038/s41586-022-05426-1. View

12.

Meier-Menches S, Neuditschko B, Janker L, Gerner M, Schmetterer K, Reichle A . A Proteomic Platform Enables to Test for AML Normalization . Front Chem. 2022; 10:826346. PMC: 8844467. DOI: 10.3389/fchem.2022.826346. View

13.

Reinhold S, Reichle A, Leiminger S, Bergler T, Hoffmann U, Kruger B . Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial. BMC Res Notes. 2011; 4:2. PMC: 3038926. DOI: 10.1186/1756-0500-4-2. View

14.

STEEL G, Peckham M . Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979; 5(1):85-91. DOI: 10.1016/0360-3016(79)90044-0. View

15.

Aouali N, Broukou A, Bosseler M, Keunen O, Schlesser V, Janji B . Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells. PLoS One. 2015; 10(6):e0130339. PMC: 4474836. DOI: 10.1371/journal.pone.0130339. View

16.

Reichle A, Vogt T, Kunz-Schughart L, Bretschneider T, Bachthaler M, Bross K . Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults. Br J Haematol. 2005; 128(5):730-2. DOI: 10.1111/j.1365-2141.2004.05359.x. View

17.

Gokbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C . Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(11):2665-2673. DOI: 10.1080/10428194.2020.1780583. View

18.

Berger A, Knudson A, Pandolfi P . A continuum model for tumour suppression. Nature. 2011; 476(7359):163-9. PMC: 3206311. DOI: 10.1038/nature10275. View

19.

Szatmari I, Gogolak P, Im J, Dezso B, Rajnavolgyi E, Nagy L . Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity. 2004; 21(1):95-106. DOI: 10.1016/j.immuni.2004.06.003. View

20.

Cazzaniga M, Cordani N, Capici S, Cogliati V, Riva F, Cerrito M . Metronomic Chemotherapy. Cancers (Basel). 2021; 13(9). PMC: 8125766. DOI: 10.3390/cancers13092236. View